Jason Coloma V - 01 Oct 2026 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

SEC form
4
Accepted by SEC
02 Oct 2026, 16:12:18 UTC
Prior SEC filing
04 Sep 2026
Next SEC filing
04 Nov 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Jason Coloma V filed Form 4 for Maze Therapeutics, Inc. (MAZE) on 02 Oct 2026.

Key facts

  • This page summarizes Jason Coloma V's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 02 Oct 2026, 16:12.

Change

  • Previous filing in this sequence was filed on 04 Sep 2026.
  • Current net transaction value: -$932,260.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001676170 Primary reporting owner

Coloma Jason V

Relationship
Chief Executive Officer, Director

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MAZE transaction

Common Stock

Sale

Transaction value
-$70,073
Shares
-2,593
Change %
-14%
Price
$27.02
Shares after
15,558
Date
01 Oct 2026
Ownership
The Coloma 2021 Irrevocable Trust
Footnotes
F1, F2, F3
MAZE transaction

Common Stock

Sale

Transaction value
-$862,186
Shares
-31,908
Change %
-14%
Price
$27.02
Shares after
191,447
Date
01 Oct 2026
Ownership
Coloma Family Trust
Footnotes
F1, F4, F5
MAZE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
27,362
Date
01 Oct 2026
Ownership
Direct
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Footnote F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.645 to $27.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4.

Footnote F3

These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.

Footnote F4

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.585 to $27.47 per share, inclusive.

Footnote F5

These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .